ArticleCureus2024
Lymphomas With Primary Gastrointestinal Presentation: A Retrospective Study Covering a Five-Year Period at a Quaternary Care Center in Southern India.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cecal Involvement of Diffuse Large B-Cell Lymphoma: A Rare Extra-Nodal Presentation.Journal of medical cases · 2025Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective Lymphomas can involve the gastrointestinal (GI) tract as a primary disease or as a secondary spread of systemic disease. The GI tract is a key site for extranodal lymphomas, with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) occurring in this region. This study aimed to analyze the demography, anatomic distribution, histological subtypes, and immunomorphological characteristics of all lymphomas with a primary GI presentation at a quaternary care hospital in southern India. Methods We conducted a retrospective study covering the period from 2018 to 2022 involving all cases of lymphomas with primary GI presentation. All the cases were categorized based on morphological and immunophenotypic criteria per the World Health Organization (WHO) 2022 classification of hematopoietic and lymphoid neoplasms. Data were analyzed by using the statistical software SPSS Statistics version 28.0 (IBM Corp., Armonk, NY). Results Out of 2,455 lymphoma cases diagnosed in the five-year study period, 156 presented with primary GI symptoms. Males constituted 113 (72.5%) cases and 43 (27.5%) patients were females. The stomach (n=81; 52%) was the most common site, followed by the small intestine (n=40; 27%), large intestine (n=33; 20%), and esophagus (n=2; 1%). Most lymphomas involving the GI tract were NHL (n=152; 97%), and the remaining included four (3%) cases of HL. Diffuse large B-cell lymphoma (DLBCL) was the most frequent (n=102; 65.3%) B-cell NHL. Eight cases of T-cell lymphomas were noted including rare entities. Conclusions This study is one of the largest of its kind involving lymphomas with primary GI presentation from India. The distribution and incidence of various entities in our study were comparable to various other studies from India and those from Western countries. GI lymphomas are heterogeneous, with distinct prognoses and treatment strategies. Hence, diagnosing them correctly would help in prognostication and providing prompt therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.